COVID 19 : MSN Labs launches Favilow 800 mg tablets

In order to address the shortage of the antiviral drug Faripiravir, to treat mild and moderate COVID-19 flu, MSN Laboratories Private Limited (MSN Labs), India’s leading integrated pharmaceutical company, announced on Wednesday the launch of its branded generic, Favilow 800 mg.

The higher strength Favilow 800 mg is priced at Rs 144 per tablet and will be available across pharmacies.

The field team of MSN Labs is also helping out with free home delivery in over 170 cities in coordination with local retail chemists for patient convenience, a company release here said.

MSN had launched the world’s most affordable branded generic of Favipiravir, Favilow, in August last year, in the strengths of 200 and 400 mg.

It claims the higher strength will improve patient compliance and experience by effectively reducing the number of tablets a patient requires per day. The launch would also address the shortages and issues faced by the patients in procuring the COVID-19 drug.

MSN successfully developed the active pharmaceutical ingredient (API) and the formulation for Favilow 800 mg in its in-house R&D and manufacturing units.

The API & FDF of Favilow matches to the International quality standards, the release added.


Post Your Comments

Back to top button